Federal Judge Reed O’Connor of the U.S. District Court for the Northern District of Texas agreed to the U.S. Food and Drug Administration’s (FDA) request to pause a lawsuit over the safety of the mifepristone pill and the drug’s mail-order distribution. The lawsuit would be delayed until either Dec. 1 or the completion of the FDA’s safety review of mifepristone, whichever comes first.
In the lawsuit, Texas and Florida asked the court to revoke the FDA’s approval of the abortion-inducing pill, saying the agency didn’t adequately evaluate its safety when it approved the drug in 2000. The lawsuit also challenged mail-order distribution of the pill.
The FDA first announced it would review mifepristone in September 2025.
Noah Brandt, spokesman for Live Action, told EWTN News, “Both agencies (The Food and Drug Administration and Health and Human Services) have seen real-world data that show the harmful effects of the abortion pill. Within 45 days of a chemical abortion, 1 in 10 women experience serious adverse events from mifepristone, the first drug in the abortion pill regimen, such as sepsis, infection, or hemorrhaging.”
You can read the complete article at EWTN News here.